{"schema_version":"secwatch.filing_event.v1","accession":"0001601830-23-000027","form_type":"8-K","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2023-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.612638+00:00","generated_at":"2026-06-14T22:23:42.584415+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Recursion appoints CMO David Mauro; completes Valence acquisition for up to ~8.1M shares","bullets":["David Mauro appointed CMO effective June 1; brings 20+ years oncology drug development experience from Codiak, Checkmate, Prelude, Advaxis.","Acquisition of Valence Discovery completed; consideration includes up to ~2.2M Class A shares and ~5.9M exchangeable shares.","Recursion assumes Valence options exercisable for up to ~0.8M Class A shares; total potential dilution up to ~8.9M shares.","Dr. Mauro will lead Recursion's five clinical programs and growing pre-clinical pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001601830-23-000027","json":"https://secwatch.observer/filing/0001601830-23-000027.json","markdown":"https://secwatch.observer/filing/0001601830-23-000027.md","text":"https://secwatch.observer/filing/0001601830-23-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000027/0001601830-23-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000027/rxrx-20230516.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T22:23:42.584415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a57796d520","claim":"Shafique Virani changed role as Interim Chief Medical Officer at RECURSION PHARMACEUTICALS, INC..","evidence_excerpt":"Shafique Virani, M.D., who has been serving in the role of Chief Corporate Development Officer and Interim Chief Medical Officer, will no longer hold the position of Interim Chief Medical Officer, effective June 1, 2023, but will continue serving in the role of Chief Corporate Development Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000027/0001601830-23-000027-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will no longer hold"},{"label":"Role","value":"Interim Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"c943296623","claim":"David Mauro was appointed as Chief Medical Officer at RECURSION PHARMACEUTICALS, INC..","evidence_excerpt":"On May 16, 2023, Recursion Pharmaceuticals, Inc. (the “Company”) announced that it has appointed David Mauro, M.D., Ph.D., to the position of Chief Medical Officer, effective June 1, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000027/0001601830-23-000027-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}